Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MVA62B

Vaccine · Immune activation · developed by GeoVax

Phase 1 Most advanced trial (none active)

GOVX Developer

3 Registered trials

What is MVA62B?

MVA62B is a vaccine based on the attenuated vaccinia Ankara virus, given by intramuscular injection. It is studied in HIV-1 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: GeoVax, Inc. (GOVX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04041674	Phase 1	HIV Infections	Withdrawn	GOVX
NCT01571960	Phase 1	HIV Infections	Completed	GOVX
NCT01378156	Phase 1	HIV-1 Infection	Completed	GOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV InfectionsHIV-1 Infection

More from GeoVax

Adenovirus-Encoding E.coli PNP Phase 1/2 GEO-CM04S1 Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GOVX page.

Follow GOVX, the company behind MVA62B

See GOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GOVX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z